194 results
8-K
EX-99.1
MDGL
Madrigal Pharmaceuticals, Inc.
7 Aug 24
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
7:06am
, but not limited to Madrigal’s ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes … objectives and/or timing objectives for Madrigal’s studies; any delays or failures in enrollment, and the occurrence of adverse safety events; risks
8-K
EX-1.1
MDGL
Madrigal Pharmaceuticals, Inc.
7 May 24
Entry into a Material Definitive Agreement
4:36pm
such termination, suspension or material modification is not related to the safety of the clinical trial or the potential efficacy … , or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, “dear healthcare provider” letter
424B3
MDGL
Madrigal Pharmaceuticals, Inc.
7 May 24
Prospectus supplement
4:34pm
and key secondary study endpoints for resmetirom, and the potential for achieving such endpoints and projections, including NASH resolution, safety … and projections regarding potential NASH or NAFLD and potential patient benefits with resmetirom, including future NASH resolution, safety, fibrosis
424B5
MDGL
Madrigal Pharmaceuticals, Inc.
7 May 24
Prospectus supplement for primary offering
4:29pm
endpoints for resmetirom, and the potential for achieving such endpoints and projections, including NASH resolution, safety, fibrosis treatment … potential NASH or NAFLD and potential patient benefits with resmetirom, including future NASH resolution, safety, fibrosis treatment, cardiovascular
S-3ASR
cc4oa1urr fxbfp4x
7 May 24
Automatic shelf registration
4:06pm
8-K
EX-99.1
9ki kjn96o
7 May 24
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
7:06am
424B5
xebnadwalls7i2
20 Mar 24
Prospectus supplement for primary offering
4:06pm
424B5
qigyzkdvn
18 Mar 24
Prospectus supplement for primary offering
4:08pm
8-K
EX-99.1
dj4qif3bgx iwm38
14 Mar 24
Regulation FD Disclosure
6:47pm
8-K
EX-99.2
u8v56 s5tipc
14 Mar 24
Regulation FD Disclosure
6:47pm
8-K
EX-99.1
t0qp2b48g4p 1m4
28 Feb 24
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full
7:01am
8-K
EX-99.1
tkbx af99
8 Jan 24
Other Events
1:45pm
CORRESP
hnjbfzu9gbdwxz2 rd
14 Dec 23
Correspondence with SEC
12:00am
UPLOAD
hrv3kalw31f okguxso
21 Nov 23
Letter from SEC
12:00am
8-K
EX-99.1
999p 2p43elhqjo1inf
6 Nov 23
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023
8:31am